NCT06383858 The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center
| NCT ID | NCT06383858 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Third Affiliated Hospital of Guangzhou Medical University |
| Condition | Preeclampsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2023-08-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2023-08-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.
Eligibility Criteria
Inclusion Criteria: * 1\) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019); * 2\) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP＋PLGF±UtA-PI in the first trimester or PLGF or sFlt-1/PLGF in the second and third trimesters to assess the risk of preeclampsia. * 3\) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form. Exclusion Criteria: * 1\) Severe fetal malformation or abnormality (no fetal heartbeat); * 2\) Those who regularly use aspirin before joining the group; * 3\) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers; * 4\) Unable to obtain follow-up and delivery information.
Contact & Investigator
Dunjin Chen, Professor
PRINCIPAL INVESTIGATOR
The Third Affiliated Hospital of Guangzhou Medical University
Frequently Asked Questions
Who can join the NCT06383858 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06383858 currently recruiting?
Yes, NCT06383858 is actively recruiting participants. Contact the research team at gzdrchen@gzhmu.edu.cn for enrollment information.
Where is the NCT06383858 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06383858 clinical trial?
NCT06383858 is sponsored by The Third Affiliated Hospital of Guangzhou Medical University. The principal investigator is Dunjin Chen, Professor at The Third Affiliated Hospital of Guangzhou Medical University. The trial plans to enroll 50,000 participants.